A Cancer Research UK Phase I trial of the Anti-CD19 DI-B4 monoclonal antibody given intravenously, weekly for four weeks in patients with advanced CD19 positive indolent B-cell malignancies.

Trial Profile

A Cancer Research UK Phase I trial of the Anti-CD19 DI-B4 monoclonal antibody given intravenously, weekly for four weeks in patients with advanced CD19 positive indolent B-cell malignancies.

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Nov 2016

At a glance

  • Drugs DI B4 (Primary)
  • Indications B cell lymphoma; Chronic lymphocytic leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 12 Jul 2016 Status changed from recruiting to completed.
    • 03 Dec 2015 Accrual to date is 76% according to United Kingdom Clinical Research Network record.
    • 05 Nov 2015 Accrual to date is 73% according to United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top